Results 31 to 40 of about 22,482 (226)

Cost-effectiveness analysis of aflibercept in combination with FOLFIRI in the treatment of patients with metastatic colorectal cancer [PDF]

Farmacia Hospitalaria, 2014
Objectives: To estimate the incremental cost per life-year gained (LYG) of aflibercept in combination with FOLFIRI as second-line treatment in metastatic colorectal cancer (mCRC) patients previously treated with oxaliplatin.
M.ª Echave, C. Pericay, C. Frías, A. Abad, M.ª J. Lamas, I. Oyagüez, M. Rubio, M. Rubio, E. Giménez, S. Naoshy, F. Joulain   +10 more
doaj   +1 more source

Clinical Response To Switch From Ranibizumab To Aflibercept In Wet Age-Related Macular Degeneration

Delhi Journal of Ophthalmology, 2021
Introduction: To assess whether switching from Ranibizumab to Aflibercept conferred benefit in visual acuity (VA) and central macular thickness (CMT) in patients with wet age-related macular degeneration (AMD).
Bhagya Weerasinghe, Chandni Gupta, Yasmin Levene, Jai Shankar   +3 more
doaj   +1 more source

Real-world efficacy and safety of 8 mg aflibercept in neovascular AMD: a case series

BMJ Open Ophthalmology
Objective This real-world retrospective case series evaluates the safety and efficacy of aflibercept 8 mg in patients diagnosed with neovascular age-related macular degeneration (nAMD).
Deepak Sambhara, Priya S. Vakharia, David A. Eichenbaum   +2 more
semanticscholar   +1 more source

Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2022
Importance Laser photocoagulation, which is the standard treatment for retinopathy of prematurity (ROP), can have adverse events. Studies of anti-vascular endothelial growth factor injections have suggested efficacy in the treatment of ROP, but few ...
A. Stahl, E. Sukgen, Wei-Chi Wu, D. Lepore, H. Nakanishi, J. Mazela, D. Moshfeghi, R. Vitti, A. Athanikar, K. Chu, Pablo Iveli, Fei Zhao, T. Schmelter, S. Leal, Evra Koefuencue, N. Azuma   +15 more
semanticscholar   +1 more source

Analysis of Aflibercept Expression in NHPs following Intravitreal Administration of ADVM-022, a Potential Gene Therapy for nAMD

Molecular Therapy: Methods & Clinical Development, 2020
Several standard-of-care therapies for the treatment of retinal disease, including aflibercept, inhibit vascular endothelial growth factor (VEGFA). The main shortcoming of these therapies is potential undertreatment due to a lack of compliance resulting ...
Szilárd Kiss, Ruslan Grishanin, Aivan Nguyen, Romeo Rosario, Judith S. Greengard, Julio Nieves, Claire M. Gelfman, Mehdi Gasmi   +7 more
doaj   +1 more source

Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial.

Ophthalmology (Rochester, Minn.)
PURPOSE To follow up the previously published comparison of aflibercept 8 mg at extended dosing intervals versus aflibercept 2 mg every 8 weeks, in patients with neovascular age-related macular degeneration (nAMD) through 48 weeks, we now report efficacy,
J. Korobelnik, P. Lanzetta, Sergio Leal, F. Holz, W. Clark, David A. Eichenbaum, Tomohiro Iida, Xiaodong Sun, Alyson J. Berliner, Andrea Schulze, Min Zhao, T. Schmelter, U. Schmidt-Ott, Xin Zhang, Peter Morgan-Warren, Z. Hasanbasic, R. Vitti, Karen W. Chu, Kim Reed, R. Bhore, Yenchieh Cheng, Zhanying Bai, Boaz Hirshberg, G. Yancopoulos, Tien Y. Wong   +24 more
semanticscholar   +1 more source

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.

The Lancet
BACKGROUND A high-dose formulation of intravitreal aflibercept (8 mg) could improve treatment outcomes in diabetic macular oedema (DMO) by requiring fewer injections than the standard comparator, aflibercept 2 mg. We report efficacy and safety results of
David M. Brown, David S. Boyer, Diana V. Do, C. Wykoff, T. Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, A. Seres, Alyson J. Berliner, Sergio Leal, R. Vitti, Karen W. Chu, Kim Reed, Rohini Rao, Yenchieh Cheng, Wei Sun, Delia Voronca, R. Bhore, U. Schmidt-Ott, T. Schmelter, Andrea Schulze, Xin Zhang, Boaz Hirshberg, G. Yancopoulos, S. Sivaprasad   +25 more
semanticscholar   +1 more source

Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma

Journal of Experimental & Clinical Cancer Research, 2016
Background To evaluate the inhibitory effects of aflibercept on the growth and subretinal invasion of retinoblastoma. Methods Xenotransplantation and orthotopic mouse models were created by injecting Y-79 cells subcutaneously and intravitreally ...
Dong Yoon Kim, Jeong A Choi, Jae-Young Koh, Young Hee Yoon   +3 more
doaj   +1 more source

Efficacy, Safety, and Injection Frequency with Novel Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: A Comparison with Existing Anti-VEGF Regimens Using a Bayesian Network Meta-Analysis

Ophthalmology and Therapy
Aflibercept 8 mg administered in extended dosing intervals has shown non-inferior visual gains and comparable safety profile to aflibercept 2 mg in the PULSAR pivotal randomized clinical trial and has the potential to reduce the treatment burden of ...
Piotr Wojciechowski, M. Wdowiak, Malgorzata Panek, I. Lunk, Joao Carrasco, Xin Zhang, Olivia Wu, J. Korobelnik, P. Lanzetta   +8 more
semanticscholar   +1 more source

Potential of Nanoparticle‐Based Phototherapies for Future Treatment of Uveal Melanoma

Advanced Science, EarlyView.
This review evaluates nanoparticle‐based phototherapies for uveal melanoma, highlighting emerging strategies to enhance tumor targeting, light delivery, and treatment precision. Preclinical data indicate improved efficacy and reduced toxicity, supporting their potential to enhance localized treatment and future translational advances. (Generated by the
Emilie Lambert, Christophe Nguyen, Sean Edward Dunn, Magali Gary‐Bobo, Jérôme Lacombe, Justin Moser, Frédéric Zenhausern, Jean‐Olivier Durand, Frédérique Cunin   +8 more
wiley   +1 more source